Innoviva (INVA) Gets a Sell from Morgan Stanley

Morgan Stanley analyst Matthew Harrison maintained a Sell rating on Innoviva (INVAResearch Report) today and set a price target of $13.00. The company’s shares opened today at $14.46.

According to TipRanks, Harrison is a 5-star analyst with an average return of 7.8% and a 53.39% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Regeneron, and Alnylam Pharma.

Currently, the analyst consensus on Innoviva is a Moderate Sell with an average price target of $14.50.

See Insiders’ Hot Stocks on TipRanks >>

INVA market cap is currently $1.01B and has a P/E ratio of 11.68.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Read More on INVA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More